Postmortem PF4 antibodies confirm a rare case of thrombosis thrombocytopenia syndrome associated with ChAdOx1 nCoV-19 anti-COVID vaccination

Int J Legal Med. 2023 Mar;137(2):487-492. doi: 10.1007/s00414-022-02910-1. Epub 2022 Oct 27.

Abstract

We report a case of cerebral venous sinus thrombosis, bilateral adrenal hemorrhage, and thrombocytopenia in a 70-year-old man found dead. He had previously received the ChAdOx1 nCoV-19 vaccine (Vaxzevria®, AstraZeneca) 18 days before, and had since developed unspecific and undiagnosed characteristics of what proved to be a rare case of vaccine-associated thrombocytopenia with thrombosis syndrome (TTS). He was found dead 1 week after the beginning of symptoms (day 25 post-vaccine). Autopsy yielded venous hemorrhagic infarction with the presence of thrombi within dural venous sinuses, and extensive hemorrhagic necrosis of the central part of the adrenal glands. Antibodies against platelet factor 4 (PF4) were strongly positive in postmortem fluids, as measured with an enzyme-linked immunosorbent assay (ELISA). This difficult diagnosis is usually made during the patient's lifetime. After eliminating differential diagnoses, we concluded on a fatal case of vaccine-induced immune TTS with positive anti-PF4 antibodies in cadaveric blood, 3 weeks after ChAdOx1 nCoV-19 vaccination. Specific search for anti-PF4 antibodies in cadaveric blood appears therefore paramount to assess postmortem cases of TTS associated with anti-COVID vaccines.

Keywords: Antibodies against platelet factor 4 (PF4); AstraZeneca; COVID-19; Death; Forensic medicine; Thrombocytopenia syndrome (TTS); Vaccination.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies
  • Autopsy
  • Cadaver
  • ChAdOx1 nCoV-19* / adverse effects
  • Humans
  • Male
  • Platelet Factor 4
  • Thrombocytopenia* / chemically induced
  • Vaccination

Substances

  • Antibodies
  • ChAdOx1 nCoV-19
  • Platelet Factor 4